New York, NY – It isn’t often that a single company has an advisory committee meeting for one product and an FDA decision for another in the same week. Even more unusual is when the two drugs are of the same therapeutic class. That’s what’s happening this week for Bristol...
Latest News
PRINCETON, N.J. –– Bristol Myers Squibb (NYSE: BMY) reinforces its hematology leadership through new research across multiple therapies for patients with lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting. Highlights include updates from the company’s targeted protein degradation pipeline, including data on first-in-class investigational lymphoma CELMoD™ agent golcadomide and first-in-class...
PRINCETON, N.J. – Bristol Myers Squibb (NYSE: BMY) announced positive topline results from the Phase 3 CheckMate -648 trial evaluating treatment with Opdivo (nivolumab) plus chemotherapy or Opdivo plus Yervoy (ipilimumab) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC). In the study, Opdivo plus chemotherapy demonstrated a statistically...
PRINCETON, N.J. — Bristol Myers Squibb (NYSE: BMY) today announced topline results from the pivotal Phase 3 ALOFT-IPF trial evaluating the efficacy, safety and tolerability of admilparant, a potential first-in-class, orally administered, potent and selective lysophosphatidic acid receptor 1 (LPA1) antagonist, in adults with idiopathic pulmonary fibrosis (IPF). The trial...
PRINCETON, N.J. — Bristol Myers Squibb (NYSE: BMY) today announced positive interim Phase 3 results from the SUCCESSOR-2 study (NCT05552976). In the trial, oral mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus carfilzomib and dexamethasone alone (Kd) in patients with...
PRINCETON, N.J. — Bristol Myers Squibb (NYSE: BMY) today announced positive top-line results from the ongoing, ex-US, Phase 2 registrational study (NCT05664737) evaluating Reblozyl® (luspatercept-aamt) versus placebo for anemia in adults with Alpha (α)-Thalassemia. The non‑transfusion‑dependent (NTD) and transfusion‑dependent (TD) cohorts of the study met their respective primary endpoints, with Reblozyl demonstrating...
PRINCETON, N.J. — Bristol Myers Squibb (NYSE: BMY) today announced positive topline results from the planned interim analysis of the ACTION-1 trial (NCT05477576) conducted by RayzeBio, Inc., a Bristol Myers Squibb company. The study met the primary endpoint with a statistically significant and clinically meaningful improvement in progression-free survival by...
PRINCETON, N.J. – Bristol Myers Squibb on Saturday released results from the Phase III CheckMate -8HW study showing that the combination of its PD-1 inhibitor Opdivo (nivolumab) and its CTLA-4 blocker Yervoy (ipilimumab) improved progression-free survival in certain metastatic colorectal cancer patients when used in the first-line setting. Patients treated...
PRINCETON, N.J. — Bristol Myers Squibb (NYSE: BMY) today announced it will present new data from its robust hematology portfolio through more than 90 company- and partner-sponsored disclosures, including 24 oral presentations, at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place in New Orleans, Louisiana, from...
PRINCETON, N.J. – Bristol Myers Squibb is pulling the plug on a trial investigating what it calls the Opdulag combination, a pairing of Opdivo (nivolumab) and relatlimab, in patients with microsatellite stable metastatic colorectal cancer. In an announcement on Friday, BMS said that data from the Phase III trial of...
